BioPharma Resources

Drug Trial Radar · NCT04646590

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19

Last checked: Nov 19, 2026Latest source record: Jan 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 28,904 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

28,904

Actual

Start

Dec 16, 2020

Primary completion

Nov 28, 2021

Study completion Dec 2022

Sponsor

Sponsor type
Industry
First posted
Nov 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled international multicenter clinical trial design will be adopted. A total of 29,000 subjects aged 18 years and above are planned to be recruited, including 750 subjects aged 18-59 years and 250 subjects aged 60 years and above in China; 21,000 subjects aged 18-59 years and 7,000 subjects aged 60 years and above will be recruited outside China. Safety and immunogenicity will be evaluated among the Chinese subjects, and efficacy, immunogenicity and safety will be evaluated among the subjects outside China. Among them, 750 subjects aged 18-59 and 250 subjects aged 60 and above from outside China and all subjects from China will be selected as the immunogenicity subgroup for immunogenicity bridging study. The IgG levels of SARS-COV-2 neutralizing antibody and RBD protein binding antibody will be detected by blood sampling before vaccination, 14 days and 6 months after full course of vaccination to evaluate the immunogenicity and immune persistence.

Conditions

  • Prevention of COVID-19
  • Safety and Efficacy

Interventions

  • Recombinant new coronavirus vaccine (CHO cell) groupBiological

    Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

  • Recombinant new coronavirus vaccine (CHO cells) placebo groupBiological

    Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The endpoint of efficacy studyTime frame: 14 days to one year after whole vaccination
  2. The endpoint of safety studyTime frame: From the first dose of vaccination until 30 days after full course of vaccination
  3. The endpoint of safety studyTime frame: From the first dose of vaccination until 12 months after full course of vaccination

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • Hunan Provincial Center for Disease Control and Prevention

    Changsha, Hunan, China

  • Biodimed Guayaquil Clinical Research Center

    Guayaquil, Guayas, Ecuador

  • Biodimed Alemania Clinical Research Center

    Quito, Pichincha, Ecuador

  • Biodimed Eloy Alfaro Clinical Research Center

    Quito, Pichincha, Ecuador

  • Fkui-Rscm

    Jakarta, Jakarta Special Capital Region, Indonesia

  • FK Unpad/RSHS

    Bandung, West Java, Indonesia

  • Shaheed Zulfiqar Ali Bhutto Medical University

    Islamabad, Pakistan

  • Aziz Fatimah Hospital

    Faisalabad, Punjab Province, Pakistan

  • Avicenna Hospital

    Lahore, Punjab Province, Pakistan

  • Central Park Teaching Hospital

    Lahore, Punjab Province, Pakistan

  • National Hospital & Medical Center

    Lahore, Punjab Province, Pakistan

  • University of Health Sciences

    Lahore, Punjab Province, Pakistan

  • Al-Shifa Trust Eye Hospital

    Rawalpindi, Punjab Province, Pakistan

  • Indus Hospital and Health Network

    Karachi, Sindh, Pakistan

  • Family Hospital No.15

    Tashkent, Uzbekistan

  • GUVD Poliklinika

    Tashkent, Uzbekistan

  • IIV Markaziy Poliklinika

    Tashkent, Uzbekistan

  • Toshkent viloyat IIV Poliklinika

    Tashkent, Uzbekistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.